SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Hepatology Consultation — Evel Knievel

PatientEvel Knievel
Date of birth1968-10-17
IdentifiersMRN HR-RB001-SYN; SSN (made up) 000-01-4927
Document date2026-01-26
AuthorMei-Ling Okonkwo, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Referral

Raised transaminases (ALT 88, AST 96 U/L) and platelets of 118 on today's tests, with spider angiomas and palmar erythema, in a 57-year-old retired stunt performer who received many blood transfusions after crashes before 1992, drinks most evenings and has type 2 diabetes. Hepatitis C antibody with reflex RNA, hepatitis A and B serology, HIV and an abdominal ultrasound are ordered. Please see him within three weeks to confirm the cause, stage his liver disease and plan treatment. [S]

Urgency: Within three weeks; sooner if he develops jaundice, ascites, bleeding or confusion. [S]

Questions for the consultant:

History of Present Illness

Mr. Knievel, 57, is seen at the request of Dr. Rasmussen two weeks after raised transaminases and low platelets were found at his first visit. He received many transfusions after crashes during his stunt career, before blood was screened for hepatitis C. The hepatitis C antibody is positive with HCV RNA 2.35 million IU/mL, genotype 1a; he has never been treated. He drank three or four drinks most evenings and has cut down to about two since the first visit. He has type 2 diabetes on metformin and chronic pain from old fractures; ibuprofen and omeprazole were stopped two weeks ago. He has had no jaundice, abdominal swelling, black stools, vomiting of blood or confusion. [S]

Historical basis. These claims are historical evidence, not findings from a modern examination.

5 later historical claims are omitted because they describe events after the index age. See the teaching note.

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 1000 mg oral tablet, one tablet by mouth twice daily with mealsOne tablet twice daily with breakfast and supperOral route2021-03-01activeS
Ibuprofen 800 mg oral tablet, one tablet three times a day for joint and back painOne tablet three times a dayOral route2024-06-01 to 2026-01-12completedS
Omeprazole 20 mg delayed-release oral capsule, one capsule daily for indigestion from ibuprofenOne capsule daily before breakfastOral route2024-06-01 to 2026-01-12completedS
Acetaminophen 500 mg oral tablet, two tablets by mouth up to twice a day as needed for pain, no more than 2 g a dayTwo tablets up to twice a day as needed; no more than 2 g a dayOral route2026-01-12activeS
Diclofenac sodium 1% topical gel, 4 g to the knees up to four times a day4 g to each knee up to four times a dayTopical route2026-01-12activeS
Carvedilol 6.25 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-01-26 to 2026-02-23completedS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-01-26activeS

Problems

ProblemClinical statusVerificationCodeProvenance
Raised transaminases (ALT 88, AST 96 U/L) and low platelets (118) on today's tests, with spider angiomas and palmar erythema, in a man of 57 who received many blood transfusions after crashes before 1992 and drinks most evenings: chronic liver disease, most likely hepatitis C, must be excluded. Hepatitis C antibody with reflex RNA, hepatitis A and B serology, HIV, liver ultrasound and hepatology review orderedresolvedconfirmed R74.01S — Synthetic presenting problem; no symptom or result of his real illness was made public. Superseded at the hepatology consultation.
Chronic hepatitis C, genotype 1a, treatment-naive, HCV RNA 2.35 million IU/mL, likely acquired through blood transfusions after crashes; synthetic modern detail linked to his publicly reported transfusion-acquired hepatitis Cactiveconfirmed B18.2S — Synthetic genotype, viral load and timing; his hepatitis C and its likely transfusion source are documented (D).
Compensated cirrhosis from hepatitis C, with alcohol as a cofactor: liver stiffness 26.8 kPa, FIB-4 4.94, nodular liver and a 14.2 cm spleen on ultrasound, platelets 118; Child-Pugh A5, MELD-Na 8; no ascites, encephalopathy, jaundice or bleedingactiveconfirmed K74.69S — Synthetic stage of liver disease linked to his documented hepatitis C and later liver transplant.
Clinically significant portal hypertension in compensated cirrhosis (liver stiffness 25 kPa or more), treated with carvedilol without screening endoscopy (Baveno VII)activeconfirmed K76.6S — Synthetic finding at the hepatology consultation.
Type 2 diabetes on metformin, A1c 7.4%activeconfirmed E11.65S — Synthetic; diabetes is documented only in his last years (D), and placing it at 57 is a synthetic choice.
Chronic pain in the back, hips, pelvis and knees after dozens of fractures from stunt crashes, including a broken pelvis; ibuprofen stopped, and managed without oral NSAIDs or opioidsactiveconfirmed G89.29S — Synthetic pain at the index age, anchored to his documented fractures and the pain of his later years.

Physical Exam

Vital signs recorded on 2026-01-26; see the referring visit's Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 136/82, pulse 78
SkinSix spider angiomas; palmar erythema; no jaundice
AbdomenFirm liver edge 2 cm below the costal margin; spleen tip palpable; no shifting dullness
NeurologicalNo asterixis

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-01-26Liver stiffness by US.transient elastography26.8kPaBelow 7 kPa normal; above 12.5 kPa cirrhosis; 25 kPa or more clinically significant portal hypertensionHighS
2026-01-26Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-01-26Total score [AUDIT-C]4{score}S
2026-01-26Pain severity - 0-10 verbal numeric rating [Score] - Reported6{score}S

Assessment

Data reviewed: Dr. Rasmussen's intake note and results: platelets 118, ALT 88, AST 96 U/L, bilirubin 1.1 mg/dL, albumin 3.6 g/dL, INR 1.1, creatinine 0.92 mg/dL, eGFR 97, A1c 7.4%, LDL 112 mg/dL; FIB-4 4.94. Serology: HCV RNA 2.35 million IU/mL, genotype 1a; hepatitis B surface antigen, core antibody and surface antibody negative; hepatitis A IgG negative; HIV negative. Ultrasound a week ago: nodular liver, coarse echotexture, no focal lesion, spleen 14.2 cm, patent portal vein with forward flow, no ascites. Transient elastography in clinic today: 26.8 kPa (reliable), controlled attenuation parameter 248 dB/m. [S]

Plan of Treatment